OCUL
Ocular Therapeutix Inc · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website ocutx.com
- Employees(FY) 274
- ISIN US67576A1007
Performance
+4.31%
1W
-24.28%
1M
+7.65%
3M
+173.76%
6M
+35.65%
YTD
-4.42%
1Y
Profile
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Investment Analysis Report: OCUL
Overview:
OCUL is a company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $835,457,215. In this report, we will conduct a comprehensive analysis of OCUL's financial statements to provide insights into its valuation, finan...
Technical Analysis of OCUL 2024-05-10
Overview:
In analyzing the technical indicators for OCUL over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and recommendations for your investm...
Recent News & Updates
- 2024-05-07 18:07
Ocular Therapeutix Inc Reports First Quarter 2024 Earnings(GuruFocus.com)
- 2024-05-07 16:41
Ocular Therapeutix: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-07 16:05
Ocular Therapeutix™ Reports First Quarter 2024 Results(GlobeNewswire)
- 2024-05-07 09:01
- 2024-05-07 04:05
Ocular Therapeutix Reports First Quarter 2024 Results(Globenewswire)
- 2024-05-06 20:16
- 2024-05-06 08:16
- 2024-05-06 07:30
- 2024-05-05 19:30
- 2024-05-03 07:30
- 2024-05-02 19:30
- 2024-05-01 07:30
- 2024-04-30 19:30
- 2024-04-24 08:30
2 Small-Cap Growth Stocks With Room To Run(Motley Fool)
- 2024-04-18 15:37
- 2024-04-18 07:00
- 2024-04-17 19:00
- 2024-04-16 16:30
The 3 Best Biotech Stocks to Buy Now: Q2 Edition(InvestorPlace)
- 2024-04-16 07:00
- 2024-04-15 19:00
- 2024-04-15 07:00
- 2024-04-14 19:00
- 2024-04-09 09:35
- 2024-04-09 07:30
- 2024-04-08 21:35
- 2024-04-08 19:30
- 2024-04-06 10:00
- 2024-04-05 22:00
- 2024-04-01 10:09
- 2024-03-26 07:30
Page 1 of 7
previousnext